Formycon Chief Sees COVID-19 Boosting Biosimilars
As Firm Offers Pipeline Update Amid Coronavirus Pandemic
Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.
You may also be interested in...
Samsung Bioepis First To File EU Lucentis Rival
Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.
Eylea Biosimilar Race Hots Up As Formycon Launches Phase III Trials
Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.
Gedeon Richter Chief Makes Biosimilars Prophecy
Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.